Details for Patent: 8,846,074
Which drugs does patent 8,846,074 protect, and when does it expire?
Patent 8,846,074 protects KYNMOBI and is included in one NDA.
This patent has thirty-nine patent family members in twenty countries.
Summary for Patent: 8,846,074
| Title: | Sublingual films | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Nathan John Bryson, Anthony John Giovinazzo, Scott David Barnhart, Michael Clinton Koons | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Sunovion CNS Development Canada ULC , Sumitomo Pharma America Inc | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US13/858,638 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Patent 8,846,074: Apomorphine Sublingual Film Claims, Patent Scope, and Kynmobi LandscapeUS Patent 8,846,074 protects a multilayer sublingual film containing apomorphine hydrochloride in one layer and high-concentration pyridoxine in another. The patent also covers specified plasticizers, starch derivatives, antioxidants, permeation enhancers, cellulose polymers, dose strengths, rapid systemic exposure, and treatment of Parkinson's disease. The principal commercial relevance is KYNMOBI, Sunovion Pharmaceuticals' apomorphine hydrochloride sublingual film for intermittent treatment of “off” episodes in patients with Parkinson's disease. The patent is composition-focused, but its dependent claims create several formulation and performance-based infringement positions. What does US Patent 8,846,074 protect?The broadest independent claim protects a pharmaceutical composition with five core limitations:
Claim 1 does not require every excipient later recited in the dependent claims. A competing product could therefore fall within claim 1 without containing a polyol, hydrolyzed starch, metabisulfite, glycerol monostearate, or a specified cellulose polymer.
The claim is narrower than a claim to any apomorphine oral film. It requires a two-layer construction and pyridoxine in the second layer. A single-layer film, a buccal film without sublingual administration, or a film using a different pH-neutralizing agent may avoid literal infringement of claim 1, subject to claim construction and the doctrine of equivalents. How should the pyridoxine limitation be interpreted?Pyridoxine is a central claim limitation, not a peripheral excipient. Claim 1 requires pyridoxine in the second layer at a stated concentration range. Claim 18 further specifies a second layer containing 65±5% pyridoxine. Claim 19 links the pyridoxine content to a pH result in unbuffered water. The claims present three related but distinct limitations:
Claim 19 is functional and test-dependent. In litigation, the parties would likely dispute the testing protocol, including:
A generic or follow-on developer could attempt design-around protection by using a different neutralizing agent, placing pyridoxine outside the second layer, using a different concentration, or changing the layer architecture. The commercial and litigation value of that strategy would depend on the specification, prosecution history, and any related continuation claims. What formulations are protected by the dependent claims?The dependent claims create a nested formulation estate around the basic apomorphine-pyridoxine film. Plasticizer claimsClaims 2 through 4 cover 3% to 12% by weight of a plasticizing agent. The claimed materials include:
These claims address film flexibility, handling, dissolution, and manufacturing properties. A formulation containing a plasticizer outside the 3% to 12% range may avoid literal infringement of claim 2, but would remain exposed to claim 1 if the core two-layer and pyridoxine limitations are satisfied. Hydrolyzed starch claimsClaims 5 and 6 cover 1% to 50% by weight of hydrolyzed starch, including:
These limitations may be important for film formation, mechanical strength, dissolution, and uniformity. A product using an unhydrolyzed starch, a synthetic polymer, or a different carbohydrate may avoid these dependent claims while remaining within claim 1. Antioxidant and metabisulfite claimsClaims 7 and 8 cover an antioxidant and specifically 0.05% to 2.5% metabisulfite. These limitations address apomorphine stability, because apomorphine is susceptible to oxidative degradation. The metabisulfite limitation is relatively concrete and potentially easier to test analytically than a broad antioxidant claim. A formulation using ascorbate, tocopherol, another sulfite concentration, or an oxygen-control strategy could avoid claim 8. Permeation-enhancer claimsClaims 9 and 10 cover 0.2% to 5% of a permeation enhancer, specifically glycerol monostearate. A product using a different permeation enhancer could avoid claim 10 but remain within claim 9 if the substitute falls within the broader functional class recognized by the claim construction. Cellulose-polymer claimsClaim 11 covers films containing one or more of the following:
These polymers are common film-forming or viscosity-modifying materials. Their use may create a straightforward dependent-claim infringement theory if the accused product's composition is disclosed in regulatory or manufacturing records. What dose strengths are covered by US 8,846,074?Claims 13 through 16 cover four dose bands:
These ranges correspond approximately to:
The ranges overlap. A 30 mg unit, for example, may fall within claims 15 and 16, depending on the product's labeled and measured content. The overlap increases the number of potentially asserted claims but may also create claim-construction and invalidity issues if the ranges are not supported by distinct technical effects. Claim 1 permits 2 to 60 mg, making it broader than the expressly recited dose claims. A product containing 45 mg could potentially satisfy claim 1 while avoiding claims 13 through 16. Does the patent cover rapid apomorphine absorption?Claim 12 requires that sublingual administration produce an average circulating concentration of at least 3 ng/mL within 5 to 15 minutes. This is a pharmacokinetic limitation. Its enforcement value depends on whether the claim is interpreted as requiring:
A competitor may avoid literal infringement if its product reaches the claimed concentration outside the specified time window. The claim may still be relevant where a product has materially similar pharmacokinetics and the patent owner asserts equivalents. Claim 12 creates a potential regulatory-to-patent interface. FDA-approved labeling, clinical pharmacology reports, and abbreviated application materials may disclose enough pharmacokinetic information to support an infringement investigation. For a generic product, the applicant's reliance on the reference product's pharmacokinetic profile could complicate a non-infringement position. What is the treatment-method scope?Claim 17 covers a method of treating Parkinson's disease by administering the claimed pharmaceutical composition sublingually in an amount effective to treat the patient. The method claim requires the underlying composition to satisfy claim 1. It does not independently cover every sublingual apomorphine product. The claim is therefore most relevant against:
The claim may support induced-infringement allegations where an approved label instructs patients to use the product for Parkinson's “off” episodes. It is less useful against an unapproved composition that lacks the required two-layer pyridoxine structure. What is the expected patent expiration date?The patent's nominal term is based on the earliest effective nonprovisional or international filing date, not simply the grant date. US Patent 8,846,074 was granted in 2014, but its statutory term runs approximately 20 years from the applicable filing date, subject to patent-term adjustment, terminal disclaimers, and any applicable patent-term extension.
The grant date should not be used as the expiration date. The controlling record is the USPTO patent bibliographic data and patent-term calculation. The Orange Book may list later-issued patents with different expiration dates that provide more immediate commercial protection for KYNMOBI. What is the Orange Book status of apomorphine sublingual film products?KYNMOBI was approved by FDA in May 2020 as apomorphine hydrochloride sublingual film for acute, intermittent treatment of “off” episodes in patients with Parkinson's disease. The product was developed by Cynapsus Therapeutics and commercialized by Sunovion Pharmaceuticals after Sunovion acquired Cynapsus in 2016. The Orange Book analysis should distinguish three categories:
US 8,846,074 is commercially relevant to the KYNMOBI formulation family. However, an Orange Book entry for a particular patent must be confirmed against the current FDA Orange Book listing for the drug's NDA. Patent ownership, listing status, and enforceability are separate questions. FDA regulatory milestones
FDA approval does not establish patent validity or infringement. It establishes regulatory approval of the drug product and its labeled use. Which companies are challenging the apomorphine film patents?No publicly established commercial generic challenge can be determined solely from the claim text. A reliable Paragraph IV assessment requires current FDA Orange Book data, ANDA litigation dockets, and notices filed under 21 U.S.C. § 355(j)(2)(B). For KYNMOBI, a Paragraph IV challenge would likely target one or more of the following:
A generic applicant could also submit a Paragraph III certification, asserting that relevant patents will expire before approval, or a section viii statement for method-of-use patents if the applicant omits the patented indication. The commercial value of those strategies depends on which patents are listed against the NDA at the time of filing. How strong is the patent estate?The patent has moderate-to-strong formulation coverage but limited breadth outside the specific film architecture. Strengths
Vulnerabilities
The strongest practical protection is likely the combination of the two-layer film and pyridoxine limitations, rather than any individual excipient claim. What generic launch scenarios exist?Scenario 1: Paragraph IV challengeA generic applicant challenges validity or asserts non-infringement. Litigation could delay approval under the Hatch-Waxman framework, subject to the applicable 30-month stay and exclusivity provisions. Scenario 2: Paragraph III certificationThe applicant accepts the listed patent claims and schedules launch after the relevant patent expiry. This is the lowest litigation-risk pathway but delays market entry. Scenario 3: Section viii carve-outThe applicant removes a patented method of use from its labeling. This strategy is more relevant to method claims than to composition claims. It is unlikely to avoid a composition patent if the approved generic product itself has the claimed two-layer structure and pyridoxine content. Scenario 4: Formulation design-aroundA competitor uses a single layer, a different neutralizing agent, a different pyridoxine location, or a non-film dosage form. This may reduce infringement risk but could also sacrifice the rapid absorption and patient-convenience advantages of the reference product. What licensing and commercial factors matter?Sunovion acquired Cynapsus for approximately $624 million in 2016, giving Sunovion control of the KYNMOBI program and associated intellectual property. The transaction indicates that the commercial value rested on the combined product, clinical program, regulatory position, and patent portfolio rather than US 8,846,074 alone. KYNMOBI's commercial exposure is tied to the Parkinson's disease “off” episode market, where alternatives include:
A film product can command commercial value through needle-free administration, but its market position depends on tolerability, oral-mucosal reactions, titration requirements, insurance coverage, and physician adoption. Commercial discontinuation or limited availability would not automatically terminate the patent. Patent enforceability and product commercialization are separate issues. How does US 8,846,074 compare with competing apomorphine products?
The patent does not create a monopoly over apomorphine as an active ingredient, Parkinson's rescue treatment, or subcutaneous delivery. Key Takeaways
Frequently Asked QuestionsDoes US 8,846,074 cover apomorphine tablets?No. The independent claim requires a film formulated for sublingual administration. A conventional tablet would not ordinarily satisfy the film limitation. Can a product avoid the patent by using pyridoxine in the first layer?Potentially. Claim 1 requires pyridoxine in the second layer. The result would depend on the complete claim set, prosecution history, specification, and any doctrine-of-equivalents theory. Does a 30 mg apomorphine film fall within multiple dose claims?Yes, potentially. A 30 mg unit can fall within the ranges of claims 15 and 16, subject to the measured amount and the applicable tolerance interpretation. Are apomorphine injections blocked by this patent?Generally no. The claims require a sublingual film, while injections use a different route and dosage form. Does FDA approval prove that the patent is valid?No. FDA approval confirms regulatory approval of the product. Patent validity, infringement, enforceability, and Orange Book listing are separate legal questions. References
More… ↓ |
Drugs Protected by US Patent 8,846,074
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-001 | May 21, 2020 | DISCN | Yes | No | 8,846,074 | ⤷ Start Trial | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Start Trial | |||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-002 | May 21, 2020 | DISCN | Yes | No | 8,846,074 | ⤷ Start Trial | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Start Trial | |||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-003 | May 21, 2020 | DISCN | Yes | No | 8,846,074 | ⤷ Start Trial | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Start Trial | |||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-004 | May 21, 2020 | DISCN | Yes | No | 8,846,074 | ⤷ Start Trial | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Start Trial | |||
| Sumitomo Pharma Am | KYNMOBI | apomorphine hydrochloride | FILM;SUBLINGUAL | 210875-005 | May 21, 2020 | DISCN | Yes | No | 8,846,074 | ⤷ Start Trial | Y | TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,846,074
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2011343429 | ⤷ Start Trial | |||
| Australia | 2017200331 | ⤷ Start Trial | |||
| Australia | 2019200138 | ⤷ Start Trial | |||
| Brazil | 112013015204 | ⤷ Start Trial | |||
| Canada | 2821756 | ⤷ Start Trial | |||
| Canada | 3115370 | ⤷ Start Trial | |||
| Canada | 3115378 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
